Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulse Dexamethasone for Podocyte Disease
NCT00065611Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jul 2003
- Primary completion
- Aug 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Presence of Complete Remission at 48 weeks. Started Jul 2003; status: completed.
02
Drugs
dexamethasone
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)
Beyond the preview
Go deeper on NCT00065611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00065611.